Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced the Korean Ministry of Intellectual Property issued a Notice of Allowance for a patent titled "Vaccine Adjuvants and Formulations" covering its breast cancer vaccine technology, licensed exclusively from Cleveland Clinic.

The allowance expands international IP coverage, complements U.S. patents, and follows a Phase 1 trial that was safe, met primary endpoints, and generated immune responses in 74% of participants, supporting further clinical development and potential future commercialization outside the U.S.

Positive

• Korean patent allowance expands international intellectual property coverage
• Phase 1 trial showed immune responses in 74% of participants
• Patent complements existing U.S. and global patents, strengthening IP estate

Negative

• Clinical program remains early-stage with only Phase 1 completed
• No regulatory approvals yet in South Korea or other markets

News Market Reaction – ANIX

+4.56%

4 alerts

+4.56% Session close to close

+2.3% Peak Tracked

-4.0% Trough Tracked

$101.81M Market Cap

0.8x Rel. Volume

In the Mar 9 session, ANIX gained 4.56%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Anixa’s breast cancer vaccine intellectual property into Korea, complement...

Analysis

This announcement extends Anixa’s breast cancer vaccine intellectual property into Korea, complementing protection in the U.S. and other regions and supporting future international development and partnering discussions. Phase 1 data showed immune responses in 74% of participants, but the program remains early-stage and pre‑revenue. In context of recent clinical progress and existing financing tools such as the Form S‑3 shelf, investors may watch for further trial design updates, regional IP additions, and partnering or funding decisions that shape development timelines.

Key Figures

Immune response rate: 74%

1 metrics

Immune response rate 74% Phase 1 breast cancer vaccine trial participants showing immune responses

Historical Context

5 past events · Latest: Mar 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 02	Annual meeting update	Positive	-0.7%	Announcement of annual meeting with clinical and regulatory progress update.
Feb 23	Conference keynote	Positive	+1.7%	Keynote highlighting ongoing Phase 1 FSHR‑mediated CAR‑T trial.
Feb 09	Clinical survival data	Positive	+0.7%	Encouraging survival observations and approval for major dose escalation.
Feb 02	Drug naming milestone	Positive	-3.3%	USAN Council approval of non‑proprietary name for CAR‑T therapy.
Jan 27	Patent allowance	Positive	-0.3%	Mexican Notice of Allowance for breast cancer vaccine IP.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical, IP, and naming milestones often saw muted or negative next-day moves, indicating a tendency for the stock to underreact or fade good news.

Recent Company History

Over the last few months, ANIX reported multiple oncology milestones, including encouraging ovarian CAR-T survival data, regulatory approval for major dose escalation, and final Phase 1 breast cancer vaccine data showing immune responses in most participants. It also secured a USAN non‑proprietary name for its CAR‑T therapy and a Mexican Notice of Allowance for the same breast cancer vaccine IP. Despite these largely positive updates, next‑day price reactions have often been modest or negative, framing today’s Korean patent allowance within a pattern of underappreciated progress.

Key Terms

notice of allowance, composition of matter, cancer immunotherapy, triple-negative breast cancer, +2 more

6 terms

notice of allowance regulatory

"has issued a Notice of Allowance for a new patent related to Anixa's breast"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

composition of matter regulatory

"will provide composition of matter protection for the Company's novel approach"

Composition of matter describes the specific chemical makeup and structure of a substance — essentially the “recipe” of which atoms or molecules are present and how they are arranged. For investors, it matters because that precise recipe is what patents, regulatory approvals, and product claims protect; control over a unique composition can create market exclusivity, influence manufacturing costs, and drive a company’s valuation or licensing potential.

cancer immunotherapy medical

"reinforcing its leadership in the field of cancer immunotherapy."

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

triple-negative breast cancer medical

"particularly in aggressive forms of the disease such as triple-negative breast cancer."

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

α-lactalbumin medical

"based on immunizing against human α-lactalbumin, a protein associated with lactation"

α-lactalbumin is a naturally occurring protein found in mammalian milk that supplies essential building blocks and supports nutrient absorption; think of it as a concentrated, high-quality protein ingredient used to boost the nutritional value of infant formula, medical nutrition and some supplements. Investors care because its use, purity, and supply affect product claims, regulatory approvals, patent positions and consumer demand in nutrition and health markets—factors that influence revenue and margins.

vaccine adjuvants medical

"The patent is titled, "Vaccine Adjuvants and Formulations," and the co-inventors"

Vaccine adjuvants are substances added to a vaccine to strengthen and shape the body’s immune response, similar to how a small amplifier makes a speaker louder so a message carries farther. They matter to investors because adjuvants can improve a vaccine’s effectiveness, reduce the amount of active ingredient needed, affect production complexity and safety profiles, and therefore influence regulatory approval, manufacturing cost and market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform

Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients

SAN JOSE, Calif., March 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued a Notice of Allowance for a new patent related to Anixa's breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in South Korea. The patent is titled, "Vaccine Adjuvants and Formulations," and the co-inventors are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both of Cleveland Clinic.

With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Korean patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward potential future regulatory approvals and commercialization efforts outside the United States.

"This newly allowed patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization. In our recently completed Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine met all major primary endpoints, was safe and well tolerated, and generated immune responses in 74% of participants, supporting continued clinical development of this novel preventive approach."

While the breast cancer survival rate is high in South Korea, the incidence rate has been increasing rapidly. In addition, unlike Western nations, the onset of breast cancer tends to occur earlier in life in South Korea. Breast cancer remains the most commonly diagnosed cancer among women worldwide, and currently there are no approved vaccines to prevent the disease.

Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue, particularly in aggressive forms of the disease such as triple-negative breast cancer.

By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention. If successful, the technology could represent one of the first preventive vaccine approaches targeting breast cancer.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-korean-ministry-of-intellectual-property-moip-for-patent-covering-breast-cancer-vaccine-technology-302707370.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa (ANIX) announce on March 9, 2026 about Korea patent coverage?

Anixa received a Notice of Allowance from the Korean Ministry of Intellectual Property for a breast cancer vaccine patent. According to the company, the patent covers formulations licensed from Cleveland Clinic and expands its international patent estate to support future development.

How does the Korean patent affect Anixa's (ANIX) global intellectual property position?

The Korean allowance strengthens Anixa's global IP footprint for its breast cancer vaccine. According to the company, it complements existing U.S. and other jurisdictions' patents and may support international development and potential partnering opportunities.

What were the Phase 1 clinical results Anixa (ANIX) referenced with the patent news?

The Phase 1 trial met major primary endpoints, was safe, and generated immune responses in 74% of participants. According to the company, these results support continued clinical development of the preventive breast cancer vaccine approach.

Does the Korean Notice of Allowance mean Anixa (ANIX) has market approval in South Korea?

No, the Notice of Allowance is an intellectual property decision, not a regulatory approval for market use. According to the company, the allowance may aid future regulatory and commercialization efforts but does not confer market authorization.

What target does Anixa's (ANIX) breast cancer vaccine use and why is it relevant?

Anixa's vaccine targets human α-lactalbumin, a lactation-associated protein expressed in some breast cancers. According to the company, this "retired" protein strategy aims to prime immune prevention while minimizing harm to normal tissue.